GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AMG-890 | AMG890
Compound class:
Nucleic acid
Comment: Olpasiran (AMG890) is an apolipoprotein A synthesis reducer. It is a GalNac-conjugated short interfering RNA (siRNA) that was designed to treat atherosclerotic cardiovascular disease in patients with elevated lipoprotein A [1-2].
We have been unable to locate a full chemical SMILES for the drug, or its HELM notation. We provide the basic nucleic acid structure for the molecule here. Full specifications for all modifications are available from its INN record. |
| No information available. |
Summary of Clinical Use  |
| Amgen are evaluating the safety and efficacy of olpasiran (AMG890) in patients with elevated serum lipoprotein A who are at high risk of atherosclerotic cardiovascular disease. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05581303 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Phase 3 Interventional | Amgen | ||
| NCT04270760 | Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study | Phase 2 Interventional | Amgen | ||
